 This study found that a recombinant adenovirus AD5-S armacran expressing the armacran BA.1 spike protein was able to generate both systemic and mucosal immune responses when delivered intranasally. These responses included neutralizing antibodies and T cells specific for armacran subvariants, as well as pre-armacran strains. Additionally, the AD5-S armacran vaccine was able to protect mice against armacran challenge. Based on these results, the authors suggest that this recombinant AD5-S armacran vaccine may be a promising candidate for use as a safe, effective, and user-friendly infection and transmission blocking vaccine. This article was authored by Qian Wang, Chen Chen Yang, Li Yin, and others.